<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Prognostic Value of Undetectable hs Troponin T in Suspected Acute Coronary Syndrome</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Mehrshad</forename><surname>Vafaie</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Angiology, Cardiology and Pneumology</orgName>
								<orgName type="institution">University Hospital of Heidelberg</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>VD</roleName><forename type="first">Anna</forename><surname>Slagman</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Department of Cardiology</orgName>
								<orgName type="department" key="dep2">Division of Emergency Medicine</orgName>
								<orgName type="institution">Charité Universitätsmedizin Berlin (Campus Virchow Klinikum and Campus Charité Mitte)</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Martin</forename><surname>Möckel</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Department of Cardiology</orgName>
								<orgName type="department" key="dep2">Division of Emergency Medicine</orgName>
								<orgName type="institution">Charité Universitätsmedizin Berlin (Campus Virchow Klinikum and Campus Charité Mitte)</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Christian</forename><surname>Hamm</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Department of Cardiology</orgName>
								<orgName type="department" key="dep2">Thorax Center</orgName>
								<orgName type="institution">Kerckhoff Heart</orgName>
								<address>
									<settlement>Bad Nauheim</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="institution">German Centre for Cardiovascular Research)</orgName>
								<address>
									<addrLine>partner site RheinMain</addrLine>
									<settlement>Frankfurt am Main</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department">Cardiology and Angiology</orgName>
								<orgName type="institution" key="instit1">Medical Clinic I</orgName>
								<orgName type="institution" key="instit2">University of Giessen</orgName>
								<address>
									<settlement>Giessen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Kurt</forename><surname>Huber</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Department of Cardiology and Internal Emergency Medicine</orgName>
								<address>
									<settlement>Wilhelminenspital, Vienna</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Christian</forename><surname>Müller</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Department of Cardiology</orgName>
								<orgName type="institution">University Hospital Basel</orgName>
								<address>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD, MBA</roleName><forename type="first">Jörn</forename><forename type="middle">O</forename><surname>Vollert</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Clinical Diagnostics</orgName>
								<address>
									<settlement>Thermo</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Stefan</forename><surname>Blankenberg</surname></persName>
							<affiliation key="aff9">
								<orgName type="department">Department of General and Interventional Cardiology</orgName>
								<orgName type="institution">University Heart Center Hamburg</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Hugo</forename><forename type="middle">A</forename><surname>Katus</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Angiology, Cardiology and Pneumology</orgName>
								<orgName type="institution">University Hospital of Heidelberg</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Christoph</forename><surname>Liebetrau</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Department of Cardiology</orgName>
								<orgName type="department" key="dep2">Thorax Center</orgName>
								<orgName type="institution">Kerckhoff Heart</orgName>
								<address>
									<settlement>Bad Nauheim</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="institution">German Centre for Cardiovascular Research)</orgName>
								<address>
									<addrLine>partner site RheinMain</addrLine>
									<settlement>Frankfurt am Main</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Evangelos</forename><surname>Giannitsis</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Angiology, Cardiology and Pneumology</orgName>
								<orgName type="institution">University Hospital of Heidelberg</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><roleName>MD, MPH</roleName><forename type="first">Julia</forename><surname>Searle</surname></persName>
							<email>julia.searle@charite.de</email>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Department of Cardiology</orgName>
								<orgName type="department" key="dep2">Division of Emergency Medicine</orgName>
								<orgName type="institution">Charité Universitätsmedizin Berlin (Campus Virchow Klinikum and Campus Charité Mitte)</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>Scientific, B.R.A.H.M.S GmbH</roleName><surname>Fisher</surname></persName>
						</author>
						<author>
							<affiliation key="aff8">
								<address>
									<settlement>Hennigsdorf</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff10">
								<orgName type="department">Division of Emergency Medicine</orgName>
								<orgName type="institution">Charité Universitätsmedizin Berlin (Campus Virchow Klinikum and Campus Charité Mitte)</orgName>
								<address>
									<addrLine>Augustenburger Platz 1</addrLine>
									<postCode>13353</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Prognostic Value of Undetectable hs Troponin T in Suspected Acute Coronary Syndrome</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">38C0D420BE7D5607B3B12F49B22BDA1A</idno>
					<idno type="DOI">10.1016/j.amjmed.2015.10.016</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:20+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Acute coronary syndrome (ACS)</term>
					<term>Acute myocardial infarction (AMI)</term>
					<term>Copeptin</term>
					<term>High-sensitivity troponin T (hsTnT)</term>
					<term>Limit of detection (LoD)</term>
					<term>Rule-out</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BACKGROUND:</head><p><s>The search for improved strategies for safe and early discharge of patients with suspected acute coronary syndrome in emergency departments is ongoing.</s><s>This Biomarkers in Cardiology (BIC)-8 biomarker substudy evaluated the usefulness of high-sensitivity troponin T (hsTnT) below or above the limit of detection (LoD) in low-to-intermediate-risk patients with suspected acute coronary syndrome in the emergency department.</s><s>METHODS: Patients were categorized into hsTnT the 99 th percentile, between the 99 th percentile and LoD, or undetectable hsTnT (&lt;LoD).</s><s>HsTnT and copeptin were measured at admission, using a copeptin cut-off of 10 pmol/L.</s><s>The primary endpoint was death and myocardial infarction within 90 days after admission.</s><s>RESULTS: Of 882 patients with all biomarker results, 577 (65.4%) had detectable hsTnT levels (LoD).</s><s>Among the 305 patients (34.6%) with undetectable hsTnT, no myocardial infarctions or deaths occurred within 90 days.</s><s>In patients with detectable hsTnT at admission (LoD but 99 th percentile), the combined endpoint occurred in 1.5% (6/410) of the copeptin-negative patients and in 6.3% (6/96) of copeptin-positive patients within 90 days (hazard ratio 4.39; 95% confidence interval, 1.42-13.61;</s><s>P ¼ .01).</s><s>In patients with an initially elevated hsTnT (14 ng/L), 9.7% (3/31) of the copeptin-negative patients and 15.4% (4/26) of the copeptin-positive patients experienced the combined endpoint (hazard ratio 1.61; 95% confidence interval, 0.36-7.17;</s><s>P ¼ .536).</s><s>CONCLUSIONS: In low-to-intermediate-risk patients with suspected acute coronary syndrome, undetectable hsTnT values at admission allow a safe discharge without occurrence of death or myocardial infarction within 90 days.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>One of the challenging tasks of emergency departments and chest pain units is ruling out acute myocardial infarction.</s><s>Chest pain is the leading symptom in about 10% of patients admitted to emergency departments, of whom only 10% are diagnosed to have an acute myocardial infarction. <ref type="bibr" target="#b0">1</ref> Guidelines demand serial measurements of cardiac biomarkers (preferentially cardiac troponins) for safe rule-out of acute myocardial infarction. <ref type="bibr" target="#b1">2</ref> Using a high-sensitivity troponin (hsTn) assay at the recommended cut-off value at the 99 th percentile of a healthy reference population, patients require observation for at least 3 hours and retesting of hsTn to achieve an appropriate sensitivity for safe rule-out of acute myocardial infarction.</s></p><p><s>Several authors have investigated using lower cut-offs for earlier rule-out of acute myocardial infarction in patients with suspected acute coronary syndrome. <ref type="bibr" target="#b2">3,</ref><ref type="bibr" target="#b3">4</ref></s><s>The limit of blank (LoB) might be hampered by inappropriate assay precision and by potential bias from a lot-to-lot variation. <ref type="bibr" target="#b4">5,</ref><ref type="bibr" target="#b5">6</ref></s><s>A recent Swedish registry on 14,636 patients demonstrated an excellent negative predictive value (NPV) for acute myocardial infarction at 30 days of 99.8% (95% confidence interval [CI], 99.7-99.9) of a highsensitivity troponin T (hsTnT) value below the limit of detection (LoD, 5 ng/L) combined with an electrocardiogram (ECG) without signs of ischemia for the rule-out of acute myocardial infarction. <ref type="bibr" target="#b6">7</ref></s><s>owever, 21% of patients with hsTnT below the LoD were still admitted to the hospital, limiting conclusions on the safety of their discharge.</s><s>The Biomarkers in Cardiology-8 (BIC-8) main study pursued a different concept, using simultaneous copeptin and troponin measurement for diagnosis and management of suspected acute coronary syndrome in the emergency department. <ref type="bibr" target="#b7">8</ref></s><s>he major finding of that study was that patients with negative troponin and negative copeptin values at admission could be discharged as safely as the standard group managed according to current guidelines.</s><s>This BIC-8 biomarker substudy constitutes a postrandomization cohort evaluating a lower hsTnT decision cut-off at the LoD.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>METHODS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study Population</head><p><s>The BIC-8 study was an international, multicenter, randomized clinical process trial.</s><s>Patients presenting to the emergency department with symptoms consistent with acute coronary syndrome who were initially tested troponin negative with the in-house routine troponin assay were enrolled between April 2011 and May 2013.</s><s>Patients with ST-elevation myocardial infarction, continuing or recurrent chest pain under therapy, and high-risk patients were excluded.</s><s>The full methods have been described in detail elsewhere. <ref type="bibr" target="#b7">8</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Endpoints</head><p><s>The primary endpoint for the current analysis was a combined endpoint of myocardial infarction and death within 90 days after admission in order to reproduce the findings of other studies. <ref type="bibr" target="#b2">3,</ref><ref type="bibr" target="#b6">7</ref></s><s>Secondary endpoints were occurrence of major adverse cardiac events and the single components within 30 and 90 days.</s><s>Major adverse cardiac events was defined as all-cause death or survived sudden cardiac arrest, acute myocardial infarction, re-hospitalization for acute coronary syndrome, acute unplanned percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG)  and documented life-threatening arrhythmias (ventricular fibrillation, ventricular tachycardia or third-degree atrioventricular block).</s><s>All potential major adverse cardiac events were adjudicated by 2 independent cardiologists who were blinded to the group assignment and copeptin result.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Biomarker Testing</head><p><s>In 4 participating centers, hsTnT was measured routinely.</s><s>For the remaining centers, hsTnT was measured from frozen blood samples collected at admission, using the electro-chemiluminescence immunoassay by Roche Diagnostics (Risch-Rotkreuz, Switzerland; LoB 3 ng/L, LoD 5 ng/L). <ref type="bibr" target="#b8">9</ref></s><s>The 99 th percentile of a healthy reference population is 14 ng/L.</s><s>Copeptin values were determined by the Kryptor ultrasensitive assay (Thermo Fisher Scientific BRAHMS, Hennigsdorf, Germany; LoD 0.9 pmol/L).</s><s>A value 10 pmol/L was considered positive.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical Analysis</head><p><s>This analysis evaluated the value of hsTnT below the LoD at admission for identification of patients at very low risk for occurrence of myocardial infarction or death within 90 days.</s><s>Additionally, combined testing of hsTnT and copeptin was evaluated for further risk stratification of patients with hsTnT values the LoD.</s><s>Patients were divided into 4 subgroups: hsTnT values 5 &lt; 14 ng/L and copeptin &lt; 10 pmol/L(1) or copeptin 10 pmol/L(2); hsTnT value 14 ng/L and copeptin &lt; 10 pmol/L(3) and 10 pmol/L(4).</s><s>For categorical variables, relative and absolute frequencies are reported.</s><s>Numeric variables are displayed as median and interquartile ranges (IQRs).</s><s>Discriminatory statistical computations were conducted by receiver operating curve (ROC) analysis and calculation of the area under the curve (AUROC).</s><s>Hazard ratios (HRs) were computed by proportional hazards regression.</s><s>Due to the low number of events, HRs were not adjusted for covariates.</s><s>In a Kaplan-Meier analysis, cumulative hazards for the respective 5biomarker test result-based groups are shown over time.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Ethical Considerations</head><p><s>This study complies with the Declaration of Helsinki.</s><s>All locally appointed ethics committees approved the research</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CLINICAL SIGNIFICANCE</head><p><s>Patients with suspected acute coronary syndrome and undetectable highsensitivity troponin T (hsTnT) at admission to the emergency department have a very low risk for adverse cardiac events within 90 days.</s><s>The use of 2 cut-offs, limit of detection and 99 th percentile, may be a safe, costeffective, and more efficient method of instant risk stratification as compared with the current standard process of using the 99 th percentile only.</s></p><p><s>protocol and informed consent was obtained from all participants.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study Population</head><p><s>Of all patients enrolled in the original study (n ¼ 902), hsTnT and copeptin values at admission were available in 882 patients (97.8%).</s><s>The majority of patients had detectable hsTnT values (65.4%, n ¼ 577; Figure <ref type="figure" target="#fig_0">1</ref>), while 34.6% (n ¼ 305) had hsTnT values below the LoD.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patient Characteristics</head><p><s>The median age was 54 years (IQR 43-67) and the majority of patients were male (63.5%, n ¼ 560).</s><s>The median GRACE score was 78 points (IQR 59-98), and 26.6% (n ¼ 230) had known coronary artery disease, 15.0% (n ¼ 131) experienced a prior myocardial infarction, 22.9% (n ¼ 199) a prior PCI, and 5.1% (n ¼ 45) CABG (Table <ref type="table" target="#tab_0">1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Clinical Characteristics</head><p><s>The majority of patients presented with chest pain (96.0%; n ¼ 844) of moderate intensity (44.5%, n ¼ 328) and a normal ECG (95.9%, n ¼ 843).</s><s>ST depressions were evident in 2.6% (n ¼ 23; Supplementary Table, Appendix, available online).</s><s>The median hsTnT value of all patients was 6 ng/L (IQR 4-9 ng/L), and 4.8 pmol/L (IQR 3.0-8.2</s><s>pmol/L; Table <ref type="table" target="#tab_0">1</ref>) for copeptin.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Outcomes</head><p><s>After 90 days, endpoint information was available in 98.3% of patients (n ¼ 867).</s><s>The primary endpoint occurred in 2.2% (19/867; Table <ref type="table" target="#tab_1">2</ref>).</s><s>In patients with hsTnT values below the LoD, no myocardial infarction or death occurred (Supplementary Figure <ref type="figure" target="#fig_0">1</ref>, Appendix, available online).</s><s>Conversely, in patients with detectable hsTnT values at admission, death or myocardial infarction occurred in 3.4% (19/563).</s><s>In the subgroup of patients with hsTnT between LoD and 99 th percentile, 1.5% of copeptin-negative patients experienced the primary endpoint (6/410), as opposed to 6.3% in the copeptin-positive subgroup (6/96; Figure <ref type="figure" target="#fig_1">2</ref>).</s><s>In patients with an initially elevated troponin value at or above the 99 th percentile, the primary endpoint was reached in 9.7% in copeptin-negative patients (3/31) and 15.4% in copeptin-positive patients (4/26).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ROC Analysis</head><p><s>In ROC analysis, the AUROC for the prediction of death or myocardial infarction was 0.829 (95% CI, 0.760-0.899)</s><s>for hsTnT and 0.741 (95% CI, 0.628-0.853)</s><s>for copeptin.</s><s>Both markers combined achieved a higher AUROC (0.849; 95% CI, 0.790-0.908;</s><s>Supplementary Figure <ref type="figure" target="#fig_1">2</ref>, Appendix, available online).</s><s>However, the AUROC of both biomarkers combined was not statistically different from the AUROC of hsTnT alone (P ¼ .349).</s><s>In patients with hsTnT between LoD and 99 th percentile, the AUROC for copeptin was 0.745 (95% CI, 0.612-0.877); in patients with hsTnT above the 99 th percentile, the AUROC was 0.583 (95% CI, 0.311-0.588).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Survival Analysis</head><p><s>For the biomarker-combination of hsTnT and copeptin, the HR for the primary endpoint was 2.56 (95% CI, 1.85-3.54;</s><s>P &lt; .0001;</s><s>Table <ref type="table" target="#tab_1">2</ref>, Figure <ref type="figure">3</ref>).</s><s>In patients with hsTnT between LoD and 99 th percentile, copeptin was a significant predictor of death or myocardial infarction (HR 4.39; 95% CI, 1.42-13.61;</s><s>P ¼ .01).</s><s>In the subgroup of patients with an initially elevated hsTnT, copeptin failed to be significant (HR 1.61; 95% CI, 0.36-7.17;</s><s>P ¼ .536).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION</head><p><s>The present BIC-8-substudy reports 2 major findings.</s><s>First, a troponin value at presentation below the LoD is associated with an excellent outcome, and copeptin does not further improve risk stratification in this very low-risk subgroup.</s><s>Outcome events were almost exclusively restricted to patients with detectable hsTnT (LoD).</s><s>In this group of patients, additional measurement of copeptin may facilitate risk stratification.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Undetectable hsTnT</head><p><s>Use of the 99 th percentile improves early rule-out and risk stratification among patients with suspected acute coronary syndrome, as compared with less sensitive, conventional troponin generations. <ref type="bibr" target="#b9">10,</ref><ref type="bibr" target="#b10">11</ref></s><s>In stable coronary artery disease, hsTnT values below the 99 th percentile were significantly associated with cardiovascular death and heart failure in the PEACE Trial. <ref type="bibr" target="#b11">12</ref></s><s>Consistently, cutoffs below the 99 th percentile predicted adverse outcomes in a stable high-risk population in the HOPE Trial. <ref type="bibr" target="#b12">13</ref></s><s>Recent population-based studies showed a gradient of risk for future cardiovascular events and an association with structural heart disease Hazards over time are shown for 3 biomarker-related subgroups: 1) hsTnT below limit of detection (LoD) (&lt;5 ng/L), 2) hsTnT low (5 &lt; 14 ng/L), and copeptin negative (&lt;10 pmol/L) and 3) hsTnT low (5 &lt; 14 ng/L) and copeptin positive (10 pmol/L).</s><s>CI ¼ confidence interval; HR ¼ hazard ratio.</s></p><p><s>starting at hsTn concentrations close to the LoD. <ref type="bibr" target="#b13">14,</ref><ref type="bibr" target="#b14">15</ref></s><s>mong patients with suspected acute coronary syndrome, the optimal cut-off for early rule-out of acute myocardial infarction is controversial.</s><s>Body et al <ref type="bibr" target="#b5">6</ref> found, among 703 patients in a British emergency department registry, that hsTnT values below the LoB were associated with an NPV of 100% and observed favorable outcomes, as only 1% of patients died or had acute myocardial infarction within 6 months.</s><s>In a prospective evaluation of 915 patients in clinical practice, only 1 patient (0.6%) with an initial hsTnT below 3 ng/L had a subsequent elevation to 17 ng/L (NPV 99.4%).</s><s>Clinical application of LoD as a cut-off is hampered by unacceptable imprecisions exceeding 20% <ref type="bibr" target="#b15">16</ref> and by a lotto-lot variation leading to a systematic underestimation of the true hsTnT concentration in affected lots. <ref type="bibr" target="#b16">17</ref></s><s>Unfortunately, the lots used by Body et al <ref type="bibr" target="#b5">6</ref> were not reported.</s><s>Bandstein et al <ref type="bibr" target="#b6">7</ref> tested hsTnT at the LoD combined with an ECG without signs of ischemia in 14,636 patients in a Swedish registry.</s><s>They found an excellent performance for rule-out of non-ST-elevation myocardial infarction and an extremely low event rate for myocardial infarction in 0.17% and for death in 0.02% at 30 days and 0.61% for myocardial infarction and 0.43% for death at 12 months.</s><s>This concept appears more attractive, as hsTnT can be measured at the LoD with an acceptable imprecision of 20%. <ref type="bibr" target="#b8">9</ref></s><s>Rubini Giménez et al 3 reported similar results in 2072 patients, where several hsTn assays had a very high NPV at the LoD for rule-out of non-ST-elevation myocardial infarction, particularly in patients presenting 3 hours or more since onset of chest pain. <ref type="bibr" target="#b2">3</ref></s><s>ur results confirm the prognostic value of a risk stratification based on the LoD.</s><s>The absence of death/myocardial infarction in this group supports the hypothesis that a single low cut-off at presentation may allow early rule-out and safe discharge of about one-third of this low-risk acute coronary syndrome population.</s><s>Nevertheless, it should be noted that the secondary endpoint of major adverse cardiac events within 30 and 90 days was reached by some patients in the low-risk subgroup with hsTnT values below LoD (2.3% and 2.6%, respectively) due to rehospitalization for acute coronary syndrome, acute unplanned PCI, and CABG (Table <ref type="table" target="#tab_1">2</ref>).</s><s>This suggests that presence and necessity of treatment of Figure <ref type="figure">3</ref> Hazard ratios (HRs) from univariate proportional hazards regression analysis for the combined endpoint (death and myocardial infarction) as well as for single endpoint components: 1) high-sensitivity troponin T (hsTnT) in 3 categories (&lt;5 ng/L, 5 &lt; 14 ng/L, and 14 ng/L); reference category is hsTnT &lt; 5 ng/L.</s><s>2) Copeptin in 2 categories (&lt;10 pmol/L and 10 pmol/L); reference category is copeptin &lt; 10 pmol/L.</s><s>3) Copeptin in patients with hsTnT below the limit of detection and 4) hsTnT 5 &lt; 14 ng/L; the reference category is copeptin &lt; 10 pmol/L.</s><s>5) Copeptin in patients with hsTnT at or above 14 ng/L; reference category is copeptin &lt; 10 pmol/L.</s><s>6) HsTnT and copeptin combined in 5 categories (a: hsTnT &lt; 5 ng/L, b: hsTnT 5 &lt; 14 ng/L and copeptin &lt; 10 pmol/L, c: hsTnT 5 &lt; 14 ng/L and copeptin 10 pmol/lL, d: hsTnT 14 ng/L and copeptin &lt; 10 pmol/L, e: hsTnT 14 ng/L and copeptin 10 pmol/L).</s><s>Reference category in this analysis was the lowest risk category (hsTnT &lt; 5 ng/L) and HRs can be interpreted as per increase in one category.</s><s>nmiss ¼ number of missing values.</s><s>CI ¼ confidence interval; HR ¼ hazard ratio; MI ¼ myocardial infarction.</s></p><p><s>coronary artery disease cannot be excluded in these patients.</s><s>Because 3 sites did not use hsTn assays for initial troponin measurement, retrospective measurement of hsTnT showed that some patients had hsTnT values above the 99 th percentile, which were negative in conventional troponin testing.</s><s>This shows a slight heterogeneity between centers with or without routine use of hsTn.</s></p><p><s>It is interesting to note that an incremental elevation of hsTnT was observed in correlation with higher prevalence of established risk factors such as diabetes, hypertension, and hyperlipidemia, with the lowest prevalence in patients with troponin levels &lt; LoD (Table <ref type="table" target="#tab_0">1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Ultrasensitive Copeptin</head><p><s>Copeptin (CT-pro-vasopressin) is a biomarker of hemodynamic stress shown to increase within 30 minutes after onset of myocardial infarction. <ref type="bibr" target="#b17">18</ref></s><s>Numerous trials provide evidence that a negative copeptin result together with a negative cardiac troponin result allows instant rule-out of myocardial infarction with an NPV far above 99%. <ref type="bibr" target="#b18">19,</ref><ref type="bibr" target="#b19">20</ref></s><s>ost incremental benefit was observed when copeptin was added to a conventional sensitive troponin assay.</s><s>Added to hsTn assays, copeptin conferred little, albeit still significant improvement of NPV and sensitivity, but did not significantly improve the diagnostic accuracy for acute myocardial infarction as assessed by the pooled AUROC curves compared with hsTn alone.</s></p><p><s>The BIC-8 main trial demonstrated that thorough clinical assessment supported by cardiac troponin and copeptin allows an early discharge as safely as current standard management (Figure <ref type="figure" target="#fig_2">4</ref>).</s><s>This appears particularly interesting for busy emergency departments in need of accelerated yet safe patient management.</s><s>In this cohort, no cases of death or myocardial infarction occurred in patients with hsTnT below the LoD, thus copeptin does not add value in this group.</s><s>Copeptin may add information to an admission hsTnT above the LoD, but this should be further investigated in larger studies including more patients with detectable hsTnT values.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Limitations</head><p><s>This is a postrandomization cohort from a prospective biomarker trial that did not randomize patients on the basis of hsTnT.</s><s>Therefore, this study is of exploratory nature and the proposed concept remains to be tested prospectively.</s><s>In addition, BIC-8 and this substudy did not test the usefulness of hsTnT and copeptin to rule out myocardial infarction, as this concept has already been demonstrated in several studies and meta-analyses.</s><s>Due to the low number of events, adjustment for further risk factors was not possible.</s><s>Because this study only tested hsTnT, the role of other troponin assays, especially conventional and highly sensitive troponin I assays, cannot be determined.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CONCLUSION</head><p><s>The use of 2 cut-offs at LoD and at the 99 th percentile may be a safe, cost-effective, and efficient method of instant risk stratification at admission.</s><s>It is proposed that one hsTnT value &lt; LoD alone may be sufficient for safe discharge from the emergency department (ED).</s><s>This strategy, however, should be tested prospectively before implementation in clinical routine.</s><s>Copeptin may be useful in patients with detectable hsTnT levels below the 99 th percentile cut-off, copeptin values below 10 pmol/L may indicate a low risk and could potentially be part of an early rule-out strategy in these patients.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1</head><label>1</label><figDesc><div><p><s>Figure 1 Patient flow.</s><s>In the Biomarkers in Cardiology (BIC)-8 main trial, 902 patients were enrolled.</s><s>Of these, 20 patients did not have high-sensitivity troponin T (hsTnT) or copeptin values available at admission.</s><s>Thus, the study population of this BIC-8 substudy consists of 882 patients with complete biomarker results at admission.</s><s>Patients were divided by their biomarker test.</s><s>Relative and absolute frequencies are shown in the respective boxes.</s></p></div></figDesc><graphic coords="3,102.67,440.45,370.75,224.90" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2</head><label>2</label><figDesc><div><p><s>Figure 2 Hazards over time as a result of Kaplan-Meier analysis in high-sensitivity troponin T (hsTnT) and copeptin subgroups.</s><s>The results of a Kaplan-Meier survival analysis are depicted.Hazards over time are shown for 3 biomarker-related subgroups: 1) hsTnT below limit of detection (LoD) (&lt;5 ng/L), 2) hsTnT low (5 &lt; 14 ng/L), and copeptin negative (&lt;10 pmol/L) and 3) hsTnT low (5 &lt; 14 ng/L) and copeptin positive (10 pmol/L).</s><s>CI ¼ confidence interval; HR ¼ hazard ratio.</s></p></div></figDesc><graphic coords="6,108.62,56.81,358.79,370.77" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 4</head><label>4</label><figDesc><div><p><s>Figure 4 Potential algorithm.</s><s>This figure summarizes the potential use of high-sensitivity troponin T (hsTnT) below the limit of detection (LoD) based on a postrandomization cohort of the randomized Biomarkers in Cardiology (BIC)-8 process study.It is proposed that one hsTnT value &lt; LoD alone may be sufficient for safe discharge from the emergency department (ED).</s><s>This strategy, however, should be tested prospectively before implementation in clinical routine.</s><s>Copeptin may be useful in patients with detectable hsTnT levels below the 99 th percentile cut-off, copeptin values below 10 pmol/L may indicate a low risk and could potentially be part of an early rule-out strategy in these patients.</s></p></div></figDesc><graphic coords="8,108.62,56.81,358.79,192.81" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><head></head><label></label><figDesc><div><p></p></div></figDesc><graphic coords="7,39.97,56.81,496.06,296.16" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc><div><p><s>Patient Characteristics of All Patients and in Subgroups Based on the Biomarker Test Results at Admission Patient characteristics as relative and absolute frequencies for categorical variables and as median and IQR for numeric variables.</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell></cell><cell cols="2">hsTnT 5 &lt; 14 ng/L (n ¼ 519)</cell><cell>hsTnT 14 ng/L (n ¼ 58)</cell><cell></cell></row><row><cell></cell><cell>All Patients</cell><cell>hsTnT &lt; 5 ng/L</cell><cell>Copeptin &lt; 10 pmol/L</cell><cell>Copeptin 10 pmol/L</cell><cell>Copeptin &lt; 10 pmol/L</cell><cell>Copeptin 10 pmol/L</cell></row><row><cell></cell><cell>(n ¼ 882)</cell><cell>(n ¼ 305)</cell><cell>(n ¼ 418)</cell><cell>(n ¼ 101)</cell><cell>(n ¼ 32)</cell><cell>(n ¼ 26)</cell></row><row><cell>Demographics</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Age (y), median (IQR)</cell><cell>54 (43-67)</cell><cell>46 (37-56)</cell><cell>58 (46-70)</cell><cell>58 (49-66)</cell><cell>69 (51-75)</cell><cell>68 (57-74)</cell></row><row><cell>Male sex</cell><cell>63.5 (560)</cell><cell>51.8 (158)</cell><cell>65.6 (274)</cell><cell>80.2 (81)</cell><cell>78.1 (25)</cell><cell>84.6 (22)</cell></row><row><cell>European ethnicity</cell><cell>86.2 (760)</cell><cell>83.9 (256)</cell><cell>87.3 (365)</cell><cell>89.1 (90)</cell><cell>84.4 (27)</cell><cell>84.6 (22)</cell></row><row><cell>Risk factors</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>BMI, median (IQR)</cell><cell>27 (24-30)</cell><cell>26 (23-29)</cell><cell>27 (24-30)</cell><cell>28 (26-31)</cell><cell>26 (24-32)</cell><cell>28 (24-30)</cell></row><row><cell>Diabetes</cell><cell>13.7 (120)</cell><cell>7.3 (22)</cell><cell>15.4 (64)</cell><cell>20.0 (20)</cell><cell>21.9 (7)</cell><cell>26.9 (7)</cell></row><row><cell>Hypertension</cell><cell>58.7 (511)</cell><cell>43.1 (129)</cell><cell>63.2 (263)</cell><cell>71.7 (71)</cell><cell>81.3 (26)</cell><cell>88.0 (22)</cell></row><row><cell>Hyperlipidemia</cell><cell>45.2 (387)</cell><cell>29.1 (86)</cell><cell>52.3 (213)</cell><cell>51.5 (50)</cell><cell>71.0 (22)</cell><cell>64.0 (16)</cell></row><row><cell>Family history of MI</cell><cell>27.1 (223)</cell><cell>26.8 (77)</cell><cell>28.6 (112)</cell><cell>22.0 (20)</cell><cell>20.0 (6)</cell><cell>34.8 (8)</cell></row><row><cell>Smoker</cell><cell>32.8 (282)</cell><cell>36.7 (110)</cell><cell>30.5 (125)</cell><cell>34.8 (32)</cell><cell>28.1 (9)</cell><cell>24.0 (6)</cell></row><row><cell>Ex-smoker</cell><cell>31.9 (274)</cell><cell>25.7 (77)</cell><cell>34.9 (143)</cell><cell>32.6 (30)</cell><cell>40.6 (13)</cell><cell>44.0 (11)</cell></row><row><cell>GRACE score, median (IQR)</cell><cell>78 (59-98)</cell><cell>68 (52-81)</cell><cell>82 (62-102)</cell><cell>85 (65-102)</cell><cell>99 (74-117)</cell><cell>98 (78-127)</cell></row><row><cell>TIMI risk score, median (IQR)</cell><cell>1 (0-3)</cell><cell>1 (0-2)</cell><cell>1 (0-3)</cell><cell>1 (0-3)</cell><cell>3 (1-3)</cell><cell>2 (1-3)</cell></row><row><cell>Medical History</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Known CAD</cell><cell>26.6 (230)</cell><cell>14.7 (44)</cell><cell>31.2 (128)</cell><cell>33.3 (33)</cell><cell>58.1 (18)</cell><cell>26.9 (7)</cell></row><row><cell>Prior MI</cell><cell>15.0 (131)</cell><cell>6.3 (19)</cell><cell>17.0 (70)</cell><cell>20.0 (20)</cell><cell>56.3 (18)</cell><cell>16.0 (4)</cell></row><row><cell>Prior PCI</cell><cell>22.9 (199)</cell><cell>11.6 (35)</cell><cell>27.3 (112)</cell><cell>27.7 (28)</cell><cell>51.6 (16)</cell><cell>30.8 (8)</cell></row><row><cell>Prior CABG</cell><cell>5.1 (45)</cell><cell>2.0 (6)</cell><cell>5.3 (22)</cell><cell>7.9 (8)</cell><cell>15.6 (5)</cell><cell>15.4 (4)</cell></row><row><cell>Chronic heart failure</cell><cell>5.9 (51)</cell><cell>3.0 (9)</cell><cell>6.9 (28)</cell><cell>9.1 (9)</cell><cell>9.4 (3)</cell><cell>8.7 (2)</cell></row><row><cell>Primary valve disease</cell><cell>7.2 (62)</cell><cell>3.7 (11)</cell><cell>9.1 (37)</cell><cell>9.0 (9)</cell><cell>16.7 (5)</cell><cell>0 (0)</cell></row><row><cell>Prior valve surgery</cell><cell>1.3 (11)</cell><cell>0.3 (1)</cell><cell>1.9 (8)</cell><cell>1.0 (1)</cell><cell>3.1 (1)</cell><cell>0 (0)</cell></row><row><cell>Cardiomyopathy</cell><cell>2.2 (19)</cell><cell>1.3 (4)</cell><cell>2.0 (8)</cell><cell>3.0 (3)</cell><cell>6.5 (2)</cell><cell>8.0 (2)</cell></row><row><cell>Renal disease</cell><cell>6.5 (56)</cell><cell>3.0 (9)</cell><cell>4.4 (18)</cell><cell>13.1 (13)</cell><cell>25.0 (8)</cell><cell>30.8 (8)</cell></row><row><cell>Biomarkers</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Copeptin (pmol/L)</cell><cell>4.8 (3.0-8.2)</cell><cell>4.2 (3.0-6.7)</cell><cell>4.2 (3.0-6.1)</cell><cell>16.4 (12.1-26.4)</cell><cell>4.6 (3.4-6.3)</cell><cell>20.5 (11.4-39.5)</cell></row><row><cell>hsTnT (ng/L)</cell><cell>6 (4-9)</cell><cell>3 (3-4)</cell><cell>7 (5.8-9.7)</cell><cell>8 (6-11)</cell><cell>19 (15-25)</cell><cell>17 (15-27)</cell></row></table><note><p><s>BMI ¼ body mass index; CABG ¼ coronary artery bypass grafting; CAD ¼ coronary artery disease; hsTnT ¼ high-sensitivity troponin T; IQR ¼ interquartile range; MI ¼ myocardial infarction; PCI ¼ percutaneous coronary intervention.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2</head><label>2</label><figDesc><div><p><s>Relative and Absolute Frequencies of Primary and Secondary Endpoints in All Patients and in Biomarker Subgroups</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>278</cell></row><row><cell></cell><cell></cell><cell></cell><cell cols="2">hsTnT 5 &lt; 14 ng/L (n ¼ 519)</cell><cell>hsTnT 14 ng/L (n ¼ 58)</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>All Patients</cell><cell>hsTnT &lt; 5 ng/L</cell><cell>Copeptin &lt; 10 pmol/L</cell><cell>Copeptin 10 pmol/L</cell><cell>Copeptin &lt; 10 pmol/L</cell><cell cols="2">Copeptin 10 pmol/L</cell><cell></cell></row><row><cell>Endpoint</cell><cell>(n ¼ 882)</cell><cell>(n ¼ 305)</cell><cell>(n ¼ 418)</cell><cell>(n ¼ 101)</cell><cell>(n ¼ 32)</cell><cell>(n ¼ 26)</cell><cell></cell><cell></cell></row><row><cell>Primary endpoint</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Death and MI within 90 days</cell><cell>2.2 (19)</cell><cell>0 (0)</cell><cell>1.5 (6)</cell><cell>6.3 (6)</cell><cell>9.7 (3)</cell><cell>15.4 (4)</cell><cell></cell><cell></cell></row><row><cell>Death within 90 days</cell><cell>0.3 (3)</cell><cell>0 (0)</cell><cell>0.5 (2)</cell><cell>1.0 (1)</cell><cell>0 (0)</cell><cell>0 (0)</cell><cell></cell><cell></cell></row><row><cell>MI within 90 days</cell><cell>1.8 (16)</cell><cell>0 (0)</cell><cell>1.0 (4)</cell><cell>5.2 (5)</cell><cell>9.7 (3)</cell><cell>15.4 (4)</cell><cell></cell><cell></cell></row><row><cell>Secondary endpoints</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Death MI within 30 days</cell><cell>2.0 (17)</cell><cell>0 (0)</cell><cell>1.2 (5)</cell><cell>5.2 (5)</cell><cell>9.7 (3)</cell><cell>15.4 (4)</cell><cell></cell><cell></cell></row><row><cell>Death within 30 days</cell><cell>0.2 (2)</cell><cell>0 (0)</cell><cell>0.2 (1)</cell><cell>1.0 (1)</cell><cell>0 (0)</cell><cell>0 (0)</cell><cell></cell><cell></cell></row><row><cell>MI within 30 days</cell><cell>1.7 (15)</cell><cell>0 (0)</cell><cell>1.0 (4)</cell><cell>4.2 (4)</cell><cell>9.7 (3)</cell><cell>15.4 (4)</cell><cell></cell><cell></cell></row><row><cell>MACE within 30 days All-cause death MI Rehospitalization for ACS Acute unplanned PCI CABG MACE within 90 days All-cause death MI Rehospitalization for ACS Acute unplanned PCI CABG intervention.</cell><cell>5.2 (45) 0.2 (2) 1.3 (11) 0.8 (7) 2.6 (23) 0.2 (2) 6.1 (53) 0.3 (3) 1.3 (11) 1.4 (12) 2.7 (23) 0.5 (4)</cell><cell>2.3 (7) 0 (0) 0 (0) 0.3 (1) 1.3 (4) 0.7 (2) 2.6 (8) 0 (0) 0 (0) 0.3 (1) 1.3 (4) 1.0 (3)</cell><cell>4.6 (19) 0.2 (1) 0.5 (2) 1.0 (4) 2.9 (12) 0 (0) 5.9 (24) 0.5 (2) 0.5 (2) 1.7 (7) 2.9 (12) 0.2 (1)</cell><cell>10.4 (10) 1.0 (1) 3.1 (3) 2.1 (2) 4.2 (4) 0 (0) 12.5 (12) 1.0 (1) 3.1 (3) 4.2 (4) 4.2 (4) 0 (0)</cell><cell>12.5 (4) 0 (0) 6.3 (2) 0 (0) 6.3 (2) 0 (0) 12.9 (4) 0 (0) 6.5 (2) 0 (0) 6.5 (2) 0 (0)</cell><cell>19.2 (5) 0 (0) 15.4 (4) 0 (0) 3.8 (1) 0 (0) 19.2 (5) 0 (0) 15.4 (4) 0 (0) 3.8 (1) 0 (0)</cell><cell>coronary</cell><cell>The American Journal of Medicine, Vol 129, No 3, March 2016</cell></row></table><note><p><s>ACS ¼ acute coronary syndrome; CABG ¼ coronary artery bypass grafting; hsTnT ¼ high sensitivity troponin T; MACE ¼ major adverse cardiac events; MI ¼ myocardial infarction; PCI ¼ percutaneous</s></p></note></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ACKNOWLEDGMENT</head><p><s>We thank the staff at the respective study sites for their collaboration in this trial.</s><s>The investigator-initiated BIC-8 trial was supported by Thermo Fisher Scientific BRAHMS GmbH without additional funding for this BIC-8 substudy.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Funding:</head><p><s>The BIC-8 main study was supported by Thermo Fisher Scientific BRAHMS GmbH, but was an investigator-initiated trial.</s><s>There was no additional funding for this BIC-8 substudy.</s><s>JOV is an employee of Thermo Fisher Scientific.</s></p><p><s>Conflict of Interest: MV reports nonfinancial support from Roche Diagnostics and Brahms during the conduct of the study.</s><s>AS reports grants from Thermo Fisher Scientific and Roche Diagnostics during the conduct of the study; grants and nonfinancial support from Thermo Fisher Scientific, and grants from Abbott Laboratories, Radiometer, Novartis, and Cardiorentis outside the submitted work.</s><s>CH reports personal fees from Thermo Fisher and Roche during the conduct of the study.</s><s>JS reports grants from Thermo Fisher Brahms and Roche Diagnostics during the conduct of the study; and grants from Abbott Laboratories, Radiometer, Novartis, and Cardiorentis outside the submitted work.</s><s>KH has nothing to disclose.</s><s>CM reports grants, personal fees, and nonfinancial support from several diagnostic companies during the conduct of the study; and grants, personal fees, and nonfinancial support from several diagnostic and therapeutic companies outside the submitted work.</s><s>JOV reports personal fees from Thermo Fisher Scientific during the conduct of the study; and personal fees and nonfinancial support from Thermo Fisher Scientific outside the submitted work; JOV is Medical Director at Thermo Fisher Scientific.</s><s>SB reports grants and personal fees from Abbott, Abbott Diagnostics, Bayer, Boehringer Ingelheim, SIEMENS, and Thermo Fisher; and personal fees from Astra Zeneca, Medtronic, Pfizer, Roche, SIEMENS Diagnostics, Novartis, and Roche outside the submitted work.</s><s>HAK reports personal fees from Roche Diagnostics during the conduct of the study; and grants from several companies outside the submitted work; in addition, HAK has a patent cardiac troponin T assay with royalties paid.</s><s>CK has nothing to disclose.</s><s>EG reports personal fees from Thermo Scientific BRAHMS GmbH and Roche Diagnostics during the conduct of the study.</s><s>MM reports grants and personal fees from Thermo Fisher Scientific and Roche Diagnostics during the conduct of the study; grants and personal fees from Thermo Fisher Scientific, grants from Abbott Laboratories, grants and personal fees from Radiometer, Novartis, and grants from Cardiorentis outside the submitted work.</s></p><p><s>Authorship: Each of the listed authors had access to the data and a role in writing the manuscript.</s><s>Specifically, the authors contributed as follows: MV, AS: Design, analysis and interpretation of data and drafting of the manuscript.</s><s>EG, JS, and MM: design and interpretation of data, drafting of the manuscript and critical revision of the manuscript for important intellectual content.</s><s>CH, KH, CM, JOV, SB, AHK, and CL: Interpretation of data, critical revision of the manuscript for important intellectual content.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>APPENDIX</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>282.e1</head><p><s>Supplementary Figure <ref type="figure">1</ref> Hazards over time as a result of Kaplan-Meier-Analysis in hsTnT subgroups.</s><s>CI ¼ confidence interval; HR ¼ hazard ratio; hsTnT ¼ high-sensitivity troponin T.</s></p><p><s>Supplementary Figure <ref type="figure">2</ref> Receiver operating curve analysis in all patients.</s><s>hsTnT ¼ high-sensitivity troponin T.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>282.e2</head><p><s>The American Journal of Medicine, Vol 129, No 3, March 2016</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Chief complaints in medical emergencies: do they relate to underlying disease and outcome? The Charite Emergency Medicine Study (CHARITEM)</title>
		<author>
			<persName><forename type="first">M</forename><surname>Mockel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Searle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Muller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Emerg Med</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="103" to="108" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Hamm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Bassand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Agewall</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="issue">23</biblScope>
			<biblScope unit="page" from="2999" to="3054" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Rapid rule out of acute myocardial infarction using undetectable levels of high-sensitivity cardiac troponin</title>
		<author>
			<persName><forename type="first">Rubini</forename><surname>Giménez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hoeller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Reichlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Cardiol</title>
		<imprint>
			<biblScope unit="volume">168</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="3896" to="3901" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Diagnostic accuracy of single baseline measurement of Elecsys Troponin T high-sensitive assay for diagnosis of acute myocardial infarction in emergency department: systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Zhelev</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Hyde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Youngman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMJ</title>
		<imprint>
			<biblScope unit="volume">350</biblScope>
			<biblScope unit="page">15</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Biological and analytical variability of a novel high-sensitivity cardiac troponin T assay</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">C</forename><surname>Vasile</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Saenger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Kroning</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Chem</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="1086" to="1090" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Rapid exclusion of acute myocardial infarction in patients with undetectable troponin using a high-sensitivity assay</title>
		<author>
			<persName><forename type="first">R</forename><surname>Body</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Carley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Mcdowell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="1332" to="1339" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Undetectable highsensitivity cardiac troponin T level in the emergency department and risk of myocardial infarction</title>
		<author>
			<persName><forename type="first">N</forename><surname>Bandstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ljung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Johansson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="issue">23</biblScope>
			<biblScope unit="page" from="2569" to="2578" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Early discharge using single cardiac troponin and copeptin testing in patients with suspected acute coronary syndrome (ACS): a randomized, controlled clinical process study</title>
		<author>
			<persName><forename type="first">M</forename><surname>Möckel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Searle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Hamm</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="369" to="376" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Analytical validation of a highsensitivity cardiac troponin T assay</title>
		<author>
			<persName><forename type="first">E</forename><surname>Giannitsis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kurz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hallermayer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Chem</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="254" to="261" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">The new high-sensitivity cardiac troponin T assay improves risk assessment in acute coronary syndromes</title>
		<author>
			<persName><forename type="first">B</forename><surname>Lindahl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Venge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>James</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am Heart J</title>
		<imprint>
			<biblScope unit="volume">160</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="224" to="229" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Diagnostic and prognostic performance of a novel high-sensitivity cardiac troponin T assay compared to a contemporary sensitive cardiac troponin I assay in patients with acute coronary syndrome</title>
		<author>
			<persName><forename type="first">M</forename><surname>Mueller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Celik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Biener</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Res Cardiol</title>
		<imprint>
			<biblScope unit="volume">101</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="837" to="845" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) Trial Investigators. A sensitive cardiac troponin T assay in stable coronary artery disease</title>
		<author>
			<persName><forename type="first">T</forename><surname>Omland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>De Lemos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Sabatine</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">361</biblScope>
			<biblScope unit="issue">26</biblScope>
			<biblScope unit="page" from="2538" to="2547" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">High-sensitivity cardiac troponin I measurement for risk stratification in a stable high-risk population</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Kavsak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Yusuf</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Chem</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1146" to="1153" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>De Lemos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Drazner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Omland</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">304</biblScope>
			<biblScope unit="issue">22</biblScope>
			<biblScope unit="page" from="2503" to="2512" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">MORGAM Investigators. High population prevalence of cardiac troponin I measured by a high-sensitivity assay and cardiovascular risk estimation: the MORGAM Biomarker Project Scottish Cohort</title>
		<author>
			<persName><forename type="first">T</forename><surname>Zeller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Tunstall-Pedoe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Saarela</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="271" to="281" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">A new season for cardiac troponin assays: it&apos;s time to keep a scorecard</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">S</forename><surname>Apple</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Chem</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="1303" to="1306" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Clinical implications of a recent adjustment to the high-sensitivity cardiac troponin T assay: user beware</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">S</forename><surname>Apple</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Jaffe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Chem</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1599" to="1600" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Release kinetics of copeptin in patients undergoing transcoronary ablation of septal hypertrophy</title>
		<author>
			<persName><forename type="first">C</forename><surname>Liebetrau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Nef</surname></persName>
		</author>
		<author>
			<persName><surname>Szardien</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Chem</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="566" to="569" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">A systematic review and collaborative meta-analysis to determine the incremental value of copeptin for rapid rule-out of acute myocardial infarction</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Lipinski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">O</forename><surname>Escárcega</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>'ascenzo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Cardiol</title>
		<imprint>
			<biblScope unit="volume">113</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1581" to="1591" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Diagnostic accuracy of combined cardiac troponin and copeptin assessment for early rule-out of myocardial infarction: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">T</forename><surname>Raskovalova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Twerenbold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">O</forename><surname>Collinson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J Acute Cardiovasc Care</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="18" to="27" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
